Cargando…
High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology
Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts: • Compared to cytol...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073357/ https://www.ncbi.nlm.nih.gov/pubmed/32206648 http://dx.doi.org/10.5468/ogs.2020.63.2.107 |
_version_ | 1783506606021935104 |
---|---|
author | Kong, Tae-Wook Kim, Miseon Kim, Young-Han Kim, Yong Beom Kim, Jayeon Kim, Jae-Weon Park, Mi Hye Park, Joo Hyun Rhee, Jeong Ho Lim, Myong Cheol Hong, Joon-Seok |
author_facet | Kong, Tae-Wook Kim, Miseon Kim, Young-Han Kim, Yong Beom Kim, Jayeon Kim, Jae-Weon Park, Mi Hye Park, Joo Hyun Rhee, Jeong Ho Lim, Myong Cheol Hong, Joon-Seok |
author_sort | Kong, Tae-Wook |
collection | PubMed |
description | Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts: • Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervical intraepithelial neoplasia. • Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the current cytology method. • The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in this age, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening interval should be no sooner than every 3 years and no longer than every 5 years. • Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPV screening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, and screening interval. |
format | Online Article Text |
id | pubmed-7073357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-70733572020-03-23 High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology Kong, Tae-Wook Kim, Miseon Kim, Young-Han Kim, Yong Beom Kim, Jayeon Kim, Jae-Weon Park, Mi Hye Park, Joo Hyun Rhee, Jeong Ho Lim, Myong Cheol Hong, Joon-Seok Obstet Gynecol Sci Position Statement Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts: • Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervical intraepithelial neoplasia. • Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the current cytology method. • The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in this age, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening interval should be no sooner than every 3 years and no longer than every 5 years. • Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPV screening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, and screening interval. Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society 2020-03 2020-02-18 /pmc/articles/PMC7073357/ /pubmed/32206648 http://dx.doi.org/10.5468/ogs.2020.63.2.107 Text en Copyright © 2020 Korean Society of Obstetrics and Gynecology http://creativecommons.org/licenses/by-nc/3.0/ Articles published in Obstet Gynecol Sci are open-access, distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Position Statement Kong, Tae-Wook Kim, Miseon Kim, Young-Han Kim, Yong Beom Kim, Jayeon Kim, Jae-Weon Park, Mi Hye Park, Joo Hyun Rhee, Jeong Ho Lim, Myong Cheol Hong, Joon-Seok High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology |
title | High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology |
title_full | High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology |
title_fullStr | High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology |
title_full_unstemmed | High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology |
title_short | High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology |
title_sort | high-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the korean society of obstetrics and gynecology and the korean society of gynecologic oncology |
topic | Position Statement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073357/ https://www.ncbi.nlm.nih.gov/pubmed/32206648 http://dx.doi.org/10.5468/ogs.2020.63.2.107 |
work_keys_str_mv | AT kongtaewook highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology AT kimmiseon highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology AT kimyounghan highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology AT kimyongbeom highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology AT kimjayeon highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology AT kimjaeweon highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology AT parkmihye highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology AT parkjoohyun highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology AT rheejeongho highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology AT limmyongcheol highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology AT hongjoonseok highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology AT highriskhumanpapillomavirustestingasaprimaryscreeningforcervicalcancerpositionstatementbythekoreansocietyofobstetricsandgynecologyandthekoreansocietyofgynecologiconcology |